Aramis Biotechnologies Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Jul 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Influenza Virus-Like Particle Production in Plants (US 10,358,652) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Mar 19, 2027The maintenance fee for Modified Norovirus VP1 Proteins and VLPS Comprising Modified Norovirus VP1 Proteins (US 11,759,512) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Method of preparing plant-derived VLPs (US 11,826,419) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Method of preparing plant-derived proteins (US 11,833,200) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Jul 30, 2027The maintenance fee for CPMV enhancer elements (US 11,884,929) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Modifying protein production in plants (US 11,959,088) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,452,210 | Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant In force · USPTO record | In force | USPTO record | |
| US 9,458,470 | Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin In force · USPTO record | In force | USPTO record | |
| US 10,190,132 | Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin In force · USPTO record | In force | USPTO record | |
| US 11,434,497 | Recombinant influenza virus-like particles (VLPS) produced in transgenic plants In force · USPTO record | In force | USPTO record | |
| US 9,492,528 | Influenza virus-like particles (VLPS) comprising hemagglutinin In force · USPTO record | In force | USPTO record | |
| US 10,272,148 | Chimeric Influenza Virus-Like Particles Comprising Hemagglutinin In force · High confidence | In force | High confidence | |
| US 11,826,419 | Method of preparing plant-derived VLPs In force · USPTO record | In force | USPTO record | |
| US 11,833,200 | Method of preparing plant-derived proteins In force · USPTO record | In force | USPTO record | |
| US 9,815,873 | Method for recovering plant-derived proteins In force · USPTO record | In force | USPTO record | |
| US 11,390,878 | Increasing protein yield in plants In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending